Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
160 participants
INTERVENTIONAL
2009-03-31
2010-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Spironolactone for Reducing Proteinuria in Diabetic Nephropathy
NCT00498537
Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria
NCT02040441
Autoregulation of Glomerular Filtration Rate in Patients With Type 1 Diabetes During Spironolactone Therapy
NCT00335413
Spironolactone in Diabetic Nephropathy
NCT00317954
Cardiovascular Protective Effect of Spironolactone in Hemodialysis
NCT00277693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Spironolactone
25 mg per day for 9 months
2
Placebo
Placebo 1 tablet per day for nine months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Spironolactone
25 mg per day for 9 months
Placebo
Placebo 1 tablet per day for nine months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diabetic nephropathy with albuminuria
* Normal renal function
* Diastolic disfunction
* Taking a IECA or ARA drug family previously
Exclusion Criteria
* Acute coronary syndrome in the three months before
* Hyperkalemia \> 5.5 mEq/L
* Pregnancy
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad de los Andes, Chile
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Departament of Internal Medicine, University of los Andes
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Los Andes
Santiago, Santiago Metropolitan, Chile
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kozie DW, Hassul M, Kimm J. Effect of tympanic membrane perforations on air caloric response in monkeys. Trans Sect Otolaryngol Am Acad Ophthalmol Otolaryngol. 1976 Mar-Apr;82(2):203-9. No abstract available.
Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SA08I20032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.